Generic Medicine Info
May be taken with or without food.
Special Precautions
Patient with severe immune deficiency; chronic Hepatitis B. Renal impairment. Children. Pregnancy and lactation. Monitoring Parameters Monitor viral load, CD4, LFT, serum creatinine. Perform Hepatitis B testing prior to initiation of therapy.
Adverse Reactions
Significant: Immune reconstitution syndrome, severe acute exacerbations of Hepatitis B, hyperpigmentation (children). Blood and lymphatic system disorders: Anaemia, neutropenia. Ear and labyrinth disorders: Otitis media. Gastrointestinal disorders: Diarrhoea, vomiting, nausea, abdominal pain, gastroenteritis, dyspepsia. General disorders and administration site conditions: Weakness, fever Immune system disorders: Allergic reaction. Infections and infestations: Infection. Investigations: Increased creatine phosphokinase, increased serum triglycerides, increased amylase, increased serum transaminases. Metabolism and nutrition disorders: Hyperglycaemia. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia. Nervous system disorders: Dizziness, headache, paraesthesia. Psychiatric disorders: Depression, insomnia, abnormal dreams. Respiratory, thoracic and mediastinal disorders: Cough, rhinitis, pneumonia, sinusitis, upper respiratory tract infection, pharyngitis. Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis.
Drug Interactions
Increased serum concentration of either emtricitabine or co-administered drugs that are eliminated by active tubular secretion. May enhance the adverse effect with lamivudine. May diminish therapeutic effect of cladribine. May decrease serum concentration with orlistat.
CIMS Class
ATC Classification
J05AF09 - emtricitabine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on emtricitabine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in